Fig. 2

Stratified by age, sex and grade, effect of MIR17HG rs17735387 on the survival of patients. The survival curve of overall survival for patients with I-II glioma (a), female patients (c), patients with age ≥ 40 years (e) and of progression free survival for patients with I-II glioma (b), female patients (d), patients with age ≥ 40 years (f)